~~WHAT IS CLAIMED IS:~~

~~1. A method of preventing, delaying or ameliorating atopic dermatitis in a breastfed infant, the method comprising:~~

~~administering~~**Claims**

~~a.~~1. Use of a composition comprising an effective amount of a *Bifidobacterium* selected from the group consisting of *B. longum, B. breve, B. bifidum, B. pseudocatenulatum, B. globosum, B. adolescentis, B. moukalabense, B. reuteri, B. pseudolongum, B. dentium, B. catenulatum, B. sp002742445, B. callitrichos, B. scardovii, B. tissieri, B. subtile, B. gallinarum, B. choerinum, B. angulatum, B. primatium, B. myosotis, B. mongoliense, B. merycicum, B. lemurum, B. stellenboschense, B. scaligerum, B. saguini, B. pullorum, B. felsineum, B. eulemuris, B. cuniculi, B. callitrichos_A, B. biavatii, B. anseris, B. vansinderenii, B. sp900551485, B. sp003952945, B. sp003952025, B. sp003952005, B. simiarum, B. pseudolongum_C, B. parmae, B. margollesii, B. kashiwanohense_A, B. italicum, B. imperatoris, B. cricetid, B. catulorum, B. callitrichidarum, B. animalis, B. aesculapii,* and combinations thereof in the manufacture of a medicament for preventing, delaying or ameliorating atopic dermatitis in a breastfed infant, wherein the composition is to be administered to the breastfed infant.

2. The ~~method~~use of claim 1, wherein the *Bifidobacterium* is selected from the group consisting of *B. longum, B. breve*, *B. kashiwanohense* and combinations thereof.

3. The ~~method~~use of claim 1 or 2, wherein the *Bifidobacterium* is a *B. longum* subspecies selected from the group consisting of *longum*, *suis*, *infantis*, and combinations thereof.

4. The ~~method~~use of any of claims 1-3, wherein the *Bifidobacterium* is *B. infantis*.

5. The ~~method~~use of any of claims 1-4, wherein the *Bifidobacterium* is mixed into breastmilk prior to ~~administering~~ the *Bifidobacterium* is to be administered to the breastfed infant.

6. The ~~method~~use of any of claims 1-5, wherein the *Bifidobacterium* is mixed into infant formula prior to ~~administering~~ the *Bifidobacterium* is to be administered to the breastfed infant.

7. The ~~method~~use of any of claims 1-6, wherein the *Bifidobacterium* is mixed with about 3 to about 5 mL of breastmilk, infant formula or water prior to ~~administering~~ the *Bifidobacterium* is to be administered to the breastfed infant.

8. The ~~method~~use of any of claims 1-7, wherein the breastfed infant is greater than 50% breastfed.
9. The ~~method~~use of any of claims 1-8, wherein the breastfed infant is exclusively breastfed.
10. The ~~method~~use of any of claims 1-9, wherein the *Bifidobacterium* is in powder form mixed with lactose.
11. The ~~method~~use of any of claims 1-10, wherein about 5 to about 15 billion CFU of the *Bifidobacterium* are to be administered to the breastfed infant.
12. The ~~method~~use of any of claims 1-11, wherein the *B. infantis* is to be administered once daily.
13. The ~~method~~use of any of claims 1-12, wherein the *B. infantis* is first to be administered within the first 2 weeks of life.
14. The ~~method~~use of any of claims 1-13, wherein the *B. infantis* is to be administered before the first 12 weeks of life.
15. The ~~method~~use of any of claims 1-14, wherein the *Bifidobacterium* is first to be administered within the first 2 weeks and until the 12th week of life.
16. The ~~method~~use of any of claims 1-15, wherein the breastfed infant has an increased risk of developing an atopic disease.
17. The ~~method~~use of any of claims 1-16, where in the *Bifidobacterium* comprises the strain EVC001.
18. ~~A method of~~Use of an effective amount of *B. infantis* in the manufacture of a medicament for preventing, delaying, or ameliorating atopic dermatitis in a breastfed infant having at least one first-degree relative with history of an atopic disease, ~~the method comprising:~~wherein the *B. infantis* is to be administered once daily to the breastfed infant, and wherein the *B. infantis* is mixed with breastmilk,

    ~~a. administering once daily an effective amount of *B. infantis* mixed with breastmilk to the breastfed infant,~~

    wherein the breastfed infant is at least 90% breastfed, and wherein the *B. infantis* is to be first administered within first 2 weeks of life.
19. The ~~method~~use of claim 18, wherein the *B. infantis* comprises strain EVC001.
20. The ~~method~~use of claim 18, or 19 wherein the *B. infantis* is mixed with about 3 to about 5 mL of breastmilk or infant formula prior to ~~administering~~ the *B. infantis* is to be administered to the breastfed infant.
21. The ~~method~~use of any of claims 18-20, wherein the breastfed infant is exclusively breastfed.

22. The ~~method~~use of any of claims 18-21, wherein the *B. infantis* is in powder form mixed with lactose.

23. The ~~method~~use of any of claims 18-22, wherein 8 billion CFU of *B. infantis* are to be administered to the breastfed infant.

24. The ~~method~~use of any of claims 18-23, wherein the *B. infantis* is to be administered once daily until the 12th week of life.

25. ~~A method of~~Use of a composition comprising an effective amount of a *Bifidobacterium* in the manufacture of a medicament for preventing, delaying or ameliorating an atopic disease selected from the group consisting of food allergy, allergic rhinitis, asthma and combinations thereof in a breastfed infant, wherein the ~~method comprising administering a~~ composition ~~comprising an effective amount of a *Bifidobacterium*~~is to be administered to the infant.

26. The ~~method~~use of claim 25, wherein the *Bifidobacterium* is selected from the group consisting of *B. longum, B. breve, B. bifidum, B. pseudocatenulatum, B. globosum, B. adolescentis, B. moukalabense, B. reuteri, B. pseudolongum, B. dentium, B. catenulatum, B. sp002742445, B. callitrichos, B. scardovii, B. tissieri, B. subtile, B. gallinarum, B. choerinum, B. angulatum, B. primatium, B. myosotis, B. mongoliense, B. merycicum, B. lemurum, B. stellenboschense, B. scaligerum, B. saguini, B. pullorum, B. felsineum, B. eulemuris, B. cuniculi, B. callitrichos_A, B. biavatii, B. anseris, B. vansinderenii, B. sp900551485, B. sp003952945, B. sp003952025, B. sp003952005, B. simiarum, B. pseudolongum_C, B. parmae, B. margollesii, B. kashiwanohense_A, B. italicum, B. imperatoris, B. cricetid, B. catulorum, B. callitrichidarum, B. animalis, B. aesculapii,* and combinations thereof ~~to the breastfed infant~~.

27. The ~~method~~use of claim 25 or 26, wherein the *Bifidobacterium* is selected from the group consisting of *B. longum, B. breve*, *B. kashiwanohense* and combinations thereof.

28. The ~~method~~use of any of claims 25-27, wherein the *Bifidobacterium* is a *B. longum* subspecies selected from the group consisting of *longum*, *suis*, *infantis*, and combinations thereof.

29. The ~~method~~use of any of claims 25-28, wherein the *Bifidobacterium* is *B. infantis*.

30. The ~~method~~use of any of claims 25-29, wherein the *Bifidobacterium* is mixed into breastmilk prior to ~~administering~~ the *Bifidobacterium* is to be administered to the breastfed infant.

31. The ~~method~~use of any of claims 25-30, wherein the *Bifidobacterium* is mixed into infant formula prior to ~~administering~~ the *Bifidobacterium* is to be administered to the breastfed infant.

32. The ~~method~~use of any of claims 25-31, wherein the *Bifidobacterium* is mixed with about 3 to about 5 mL of breastmilk, infant formula, or water prior to ~~administering~~ the *Bifidobacterium* is to be administered to the breastfed infant.

33. The ~~method~~use of any of claims 25-32, wherein the breastfed infant is greater than 50% breastfed.

34. The ~~method~~use of any of claims 25-33, wherein the breastfed infant is exclusively breastfed.

35. The ~~method~~use of any of claims 25-34, wherein the *Bifidobacterium* is in powder form mixed with lactose.

36. The ~~method~~use of any of claims 25-35, wherein about 5 to about 15 billion CFU of the *Bifidobacterium* are to be administered to the breastfed infant.

37. The ~~method~~use of any of claims 25-36, wherein the *B. infantis* is to be administered once daily.

38. The ~~method~~use of any of claims 25-37, wherein the *B. infantis* is to be first administered within the first 2 weeks of life.

39. The ~~method~~use of any of claims 25-38, wherein the *B. infantis* is to be administered before the first 12 weeks of life.

40. The ~~method~~use of any of claims 25-39, wherein the *Bifidobacterium* is to be first administered within the first 2 weeks and until the 12th week of life.

41. The ~~method~~use of any of claims 25-40, wherein the breastfed infant has an increased risk of developing the atopic disease.

42. The ~~method~~use of any of claims 25-41, where in the *Bifidobacterium* comprises the strain EVC001.

43. ~~A method of~~Use of a composition comprising an effective amount of a *Bifidobacterium* in the manufacture of a medicament for improving infantile colic, infant sleep or infant anthropometrics in a breastfed infant, wherein the ~~method comprising administering a~~ composition ~~comprising an effective amount of a *Bifidobacterium*~~is to be administered to the infant.

44. The ~~method~~use of claim 43, wherein the *Bifidobacterium* is selected from the group consisting of *B. longum, B. breve, B. bifidum, B. pseudocatenulatum, B. globosum, B. adolescentis, B. moukalabense, B. reuteri, B. pseudolongum, B. dentium, B. catenulatum, B. sp002742445, B. callitrichos, B. scardovii, B. tissieri, B. subtile, B.*

gallinarum, B. choerinum, B. angulatum, B. primatium, B. myosotis, B. mongoliense, B. merycicum, B. lemurum, B. stellenboschense, B. scaligerum, B. saguini, B. pullorum, B. felsineum, B. eulemuris, B. cuniculi, B. callitrichos_A, B. biavatii, B. anseris, B. vansinderenii, B. sp900551485, B. sp003952945, B. sp003952025, B. sp003952005, B. simiarum, B. pseudolongum_C, B. parmae, B. margollesii, B. kashiwanohense_A, B. italicum, B. imperatoris, B. cricetid, B. catulorum, B. callitrichidarum, B. animalis, B. aesculapii, and combinations thereof ~~to the breastfed infant~~.

45. The ~~method~~use of claim 43 or 44, wherein the *Bifidobacterium* is selected from the group consisting of *B. longum, B. breve*, *B. kashiwanohense* and combinations thereof.
46. The ~~method~~use of claim 45, wherein the *Bifidobacterium* is a *B. longum* subspecies selected from the group consisting of *longum*, *suis*, *infantis*, and combinations thereof.
47. The ~~method~~use of any of claims 43-46, wherein the *Bifidobacterium* is *B. infantis*.
48. The ~~method~~use of any of claims 43-47, wherein the *Bifidobacterium* is mixed into breastmilk prior to ~~administering~~ the *Bifidobacterium* is to be administered to the breastfed infant.
49. The ~~method~~use of any of claims 43-48, wherein the *Bifidobacterium* is mixed into infant formula prior to ~~administering~~ the *Bifidobacterium* is to be administered to the breastfed infant.
50. The ~~method~~use of any of claims 43-49, wherein the *Bifidobacterium* is mixed with about 3 to about 5 mL of breastmilk, infant formula, or water prior to ~~administering~~ the *Bifidobacterium* is to be administered to the breastfed infant.
51. The ~~method~~use of any of claims 43-50, wherein the breastfed infant is greater than 50% breastfed.
52. The ~~method~~use of any of claims 43-51, wherein the breastfed infant is exclusively breastfed.
53. The ~~method~~use of any of claims 43-52, wherein the *Bifidobacterium* is in powder form mixed with lactose.
54. The ~~method~~use of any of claims 43-53, wherein about 5 to about 15 billion CFU of the *Bifidobacterium* are to be administered to the breastfed infant.
55. The ~~method~~use of any of claims 43-54, wherein the *B. infantis* is to be administered once daily.

56. The ~~method~~use of any of claims 43-55, wherein the *B. infantis* is to be first administered within the first 2 weeks of life.

57. The ~~method~~use of any of claims 43-56, wherein the *B. infantis* is to be administered before the first 12 weeks of life.

58. The ~~method~~use of any of claims 43-57, wherein the *Bifidobacterium* is to be first administered within the first 2 weeks and until the 12th week of life.

59. The ~~method~~use of any of claims 43-58, wherein the breastfed infant has an increased risk of developing the atopic disease.

60. The ~~method~~use of any of claims 43-59, where in the *Bifidobacterium* comprises the strain EVC001.

——A composition comprising an effective amount of a *Bifidobacterium* for use in therapy.

——

61.